Tuesday 9 June 2026

One To Watch

SFA Therapeutics

A clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases.

Company Overview

Want to Update your Company's Profile?


Latest SFA Therapeutics News

New chief operating officer appointed at SFA Therapeutics
16 July 2024
SFA Therapeutics names CMO to strengthen management team
3 May 2024
More SFA Therapeutics news >


Today's issue

MHRA nod for Janssen’s Imaavy
Biotechnology
MHRA nod for Janssen’s Imaavy
9 June 2026
Pharmaceutical
MHRA launches AI sandbox to support medicines development and drug safety
9 June 2026
Biotechnology
AmMax Bio licenses ADC technology from Lonza
9 June 2026
Biotechnology
ARK Invest backs Cellares with $20 million as automated cell therapy manufacturing gains momentum
9 June 2026
Pharmaceutical
AlzeCure inks deal with Lilly for Alzheimer’s project
9 June 2026
Pharmaceutical
AstraZeneca advances oral GLP-1 elecoglipron into Phase III
9 June 2026
Biotechnology
Cartesian strikes licensing agreement with WestGene
9 June 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze